Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
about
Many multiple myelomas: making more of the molecular mayhemTargeted treatments for multiple myeloma: specific role of carfilzomibMolecular pathogenesis of multiple myeloma: basic and clinical updatesDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsAdvances in understanding prognosis in myeloma.Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.How I treat plasma cell leukemia.Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomibCarfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myelomaQuantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma.Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trialsInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma.The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.European perspective on multiple myeloma treatment strategies: update following recent congressesLenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaCytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trialTreatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTDOutcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell TransplantationMolecular pathogenesis of multiple myeloma and its premalignant precursor.The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter AnalysisSerum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.Genetic aberrations in multiple myeloma characterized by cIg-FISH: a Brazilian context.
P2860
Q26852892-E10564DF-6BB4-46F0-9601-AB7D2E42B72EQ26996524-36797EF5-BE69-4D73-A616-7E666DFE5B7CQ27026205-D435CC5F-D2B6-44FE-8D20-0B4BE2D8BD1EQ27692033-C890CBB1-17F4-4436-B980-58D993E69EF1Q28084683-8B0BC164-EF23-4562-83C1-079049EB320FQ30244061-1F7064E3-0D8A-4A72-84A5-7EA437A43EB9Q30424188-7223ABB4-F071-4E67-BBBC-ED07084C8F69Q30571858-5815A2D7-44B3-4B7A-A7DE-39CE28F29B22Q31154933-D9923B88-AE74-439D-96B5-3AF2E9A32887Q33402555-03EEA8BA-C1D2-4649-8D7E-38BC759623FEQ33685126-8B5EB874-806C-40F3-ADF3-6D0E323BF959Q33785935-20099AF4-6FD1-47C8-BDE7-C51AB282A593Q34115051-C4582E46-2C45-4B1F-AE37-824070FF49A2Q34149903-4CBB5B35-81E8-471C-A905-93EE541BC297Q34173892-F7B39EB7-80A6-4D49-BF8B-AF52550DC52AQ34413764-57C7F1EF-6743-450F-A396-814B5F6F0EF1Q34773850-A5642607-EC91-4C10-955E-AA3B48B7C029Q34993904-2194ECCE-EF42-43DD-8419-1325D4A850B6Q35171777-3045B2E4-84BE-4EB0-8236-651F8B46AFB6Q35187880-8CE5EE82-4771-423A-8060-3BE89E1E7BEEQ35265979-80038879-AEE0-4C12-8F7E-0F39F61E9D09Q35651684-7592CEA9-96E5-4276-AB10-55FA6939194EQ35760754-51365489-1EB4-449C-BBC8-FE93E717CC6CQ35802414-8219909C-2272-463B-8F6E-1C5AE610662AQ35849219-F8FCD6A8-93D9-41B3-AC50-E9C5C42A3372Q35868171-CB208937-6630-491F-B074-7D4636EDA4F4Q35921897-9E62BA28-01F0-4234-A5AE-56ACF892BCC9Q35932154-F7101444-A1CC-4614-98F1-86CD3EB57D25Q35984702-35AC4A17-D75E-4031-800E-87B9DA951733Q35989943-312EA26D-C01A-4D4C-83EA-0E78573C8277Q36012111-1DE90657-6EE2-43C6-8813-B19741F867B9Q36115674-6D1D584D-3824-4431-92F8-F2272F54736BQ36138646-28AD1217-3AAD-4B37-B9BB-BEF4D14A9308Q36162623-638B6135-58DE-43E9-9103-4A06670D0DF1Q36279610-36E3DE6E-7354-4113-B186-65BDD6D1B633Q36290238-6F9813D5-3956-4F54-A0EE-1B0E81C0196CQ36316188-17A595BC-572E-477D-8FA3-FA2B770321ACQ36562341-78008782-25B6-4540-85A2-E72DE6908331Q36595290-BC4C1CDF-8F76-4F4D-84A2-B35894F6DC9CQ36793582-5D9068AC-1FB4-48B0-83DF-3940C154310A
P2860
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Bortezomib plus dexamethasone induction improves outcome of patients with t
@nl
Bortezomib plus dexamethasone ...... ome of patients with del(17p).
@en
type
label
Bortezomib plus dexamethasone induction improves outcome of patients with t
@nl
Bortezomib plus dexamethasone ...... ome of patients with del(17p).
@en
prefLabel
Bortezomib plus dexamethasone induction improves outcome of patients with t
@nl
Bortezomib plus dexamethasone ...... ome of patients with del(17p).
@en
P2093
P50
P356
P1476
Bortezomib plus dexamethasone ...... come of patients with del(17p)
@en
P2093
Anne-Marie Stoppa
Brigitte Kolb
Catherine Guerin-Charbonnel
Claire Mathiot
Cyrille Hulin
Denis Caillot
Gérald Marit
Jean-Luc Harousseau
Laurent Voillat
Lotfi Benboubker
P304
P356
10.1200/JCO.2010.28.3945
P407
P577
2010-07-19T00:00:00Z